Cisatracurium Besylate Injection, USP, 10mg per 5mL (2 mg per mL), Single-Dose Vial (NDC 71288-712-05), packaged as 10 x 5 mL Single-Dose Vials per carton (NDC 71288-712-06), Rx only, Mfd. for Meitheal Pharmaceuticals, Chicago, IL 60631.
Published March 3, 2021 · Recall initiated: January 27, 2021
Summary
FDA records drug Class I recall D-0286-2021, published March 3, 2021 and initiated January 27, 2021. Recalling firm: Meitheal Pharmaceuticals Inc; Status: Terminated; Reported quantity: 34,860 vials; Lot: Lot C11507A. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: Label mix-up: Carton of Cisatracurium Besylate Injection, USP was observed to contain ten vials mislabeled as Phenylephrine Hydrochloride Injection, USP, but confirmed to contain Cisatracurium
What to do
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get an email if CISATRACURIUM BESYLATE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CISATRACURIUM BESYLATE
- Manufacturer
- Meitheal Pharmaceuticals Inc
- Distributor
- Nationwide USA
- Lot
- Lot C11507A
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDACisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton, RxDecember 24, 2025
- FDACisatracurium Besylate Injection USP, 200mg/20mL*(10mg/mL), 10 x 20 mL Single-dose Vials per Carton, Rx Only,December 24, 2025
- FDACisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only,December 24, 2025
- FDALeucovorin Calcium for Injection, USP, 350 mg/vial, Rx only, labeled as a) Teva Parenteral Medicines, Inc.,March 3, 2021
- FDAImatinib Mesylate Tablets 100mg, packaged as a) 90-count bottles (NDC 43598-344-90); and b) For InstitutionalMarch 3, 2021
- FDAMethyIPREDNISolone Acetate Injectable Suspension USP, 400 mg/5 mL (80 mg/mL), 5 mL Multiple-Dose Vial, RxMarch 3, 2021
Questions about this recall
Was Cisatracurium Besylate Injection, USP, 10mg per 5mL (2 mg per mL), Single-Dose Vial (NDC 71288-712-05), packaged as 10 x 5 mL Single-Dose Vials per carton (NDC 71288-712-06), Rx only, Mfd. for Meitheal Pharmaceuticals, Chicago, IL 60631. recalled?
Yes. FDA published recall D-0286-2021 on March 3, 2021. Reported hazard: Labeling: Label mix-up: Carton of Cisatracurium Besylate Injection, USP was observed to contain ten vials mislabeled as Phenylephrine Hydrochloride Injection, USP, but confirmed to contain Cisatracurium
What should I do if I have this product?
Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CISATRACURIUM BESYLATE.